Ki67 targeted strategies for cancer therapy

被引：224
|
作者：
Yang, C. [1 ]
Zhang, J. [1 ]
Ding, M. [1 ,2 ]
Xu, K. [1 ,2 ]
Li, L. [1 ]
Mao, L. [1 ,2 ]
Zheng, J. [1 ]
机构：
[1] Xuzhou Med Univ, Jiangsu Key Lab Biol Canc Therapy, Xuzhou 221002, Peoples R China
[2] Univ Med Coll, Affiliated Hosp, Dept Urinary Surg, Xuzhou 221000, Peoples R China
来源：
CLINICAL & TRANSLATIONAL ONCOLOGY | 2018年 / 20卷 / 05期
关键词：
Ki67; Gene therapy; Renal cancer; siRNA; Target therapy; Proliferation; PROLIFERATION-ASSOCIATED ANTIGEN; SELECTIVE ADENOVIRUS ONYX-015; SMALL-INTERFERING-RNA; PHASE-I TRIAL; ONCOLYTIC ADENOVIRUS; ANTISENSE OLIGONUCLEOTIDE; PROSTATE-CANCER; BREAST-CANCER; INTRAVENOUS-INFUSION; ANTITUMOR-ACTIVITY;
D O I：
10.1007/s12094-017-1774-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Ki67 is a well-known proliferation marker for the evaluation of cell proliferation. Numerous studies have indicated that Ki67 index independently predicts cancer progression. Moreover, because Ki67 is highly expressed in malignant cells but almost could not be detected in normal cells, it has become a promising target for cancer therapy. In this review, we summarize recent advances in Ki67 targeted cancer therapy. In particular, we highlight recent development on the exploitation of Ki67 promoter to drive the expression of siRNAs or therapeutic genes in cancer cells specifically. The use of Ki67 as an attractive target opens a new avenue for cancer therapy.
引用
收藏
页码：570 / 575
页数：6
相关论文
共 50 条
  • [41] Questions about Ki67 staining in luminal breast cancer
    Kadri Altundag
    Breast Cancer Research and Treatment, 2018, 167 : 599 - 599
  • [42] The expression and clinical significance of clusterin and ki67 in cervical cancer
    Shrestha, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [43] Reply to Ki67 in breast cancer: a useful prognostic marker!
    Denkert, C.
    von Minckwitz, G.
    ANNALS OF ONCOLOGY, 2014, 25 (02) : 542 - 543
  • [44] Detecting of gastric cancer by Bcl-2 and Ki67
    Zhou, Yongli
    Li, Yandong
    Zheng, Jianyun
    Liu, Kaige
    Zhang, Hongmei
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (06): : 7287 - 7290
  • [45] Questions about Ki67 staining in luminal breast cancer
    Altundag, Kadri
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 167 (02) : 599 - 599
  • [46] Value of Ki67 in breast cancer: the debate is still open
    Colozza, Mariantonietta
    Sidoni, Angelo
    Piccart-Gebhart, Martine
    LANCET ONCOLOGY, 2010, 11 (05): : 414 - 415
  • [47] Telomerase and ki67 immumohistochemistry as diagnostic markers for cervical cancer
    Heras, A
    Ghirardi, G
    Maldonado, F
    Córdova, S
    Arias-Stella, J
    LABORATORY INVESTIGATION, 2003, 83 (01) : 192A - 192A
  • [48] Telomerase and Ki67 immunohistochemistry as diagnostic markers for cervical cancer
    Heras, A
    Ghirardi, G
    Maldonado, F
    Córdova, S
    Arias-Stella, J
    MODERN PATHOLOGY, 2003, 16 (01) : 192A - 192A
  • [49] Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer
    Rocca, Andrea
    Farolfi, Alberto
    Maltoni, Roberta
    Carretta, Elisa
    Melegari, Elisabetta
    Ferrario, Cristiano
    Cecconetto, Lorenzo
    Sarti, Samanta
    Schirone, Alessio
    Fedeli, Anna
    Andreis, Daniele
    Pietri, Elisabetta
    Ibrahim, Toni
    Montalto, Erika
    Amadori, Dino
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 152 (01) : 57 - 65
  • [50] Evaluation of Ki67 as a useful routine marker in breast cancer
    Bhagwat, P.
    Ally, M.
    Moorehead, J.
    VIRCHOWS ARCHIV, 2014, 465 : S108 - S108
12345